PH12020550567A1 - Ring-fused thiazolino 2-pyridones in combination with a drug against tuberculosis - Google Patents

Ring-fused thiazolino 2-pyridones in combination with a drug against tuberculosis

Info

Publication number
PH12020550567A1
PH12020550567A1 PH12020550567A PH12020550567A PH12020550567A1 PH 12020550567 A1 PH12020550567 A1 PH 12020550567A1 PH 12020550567 A PH12020550567 A PH 12020550567A PH 12020550567 A PH12020550567 A PH 12020550567A PH 12020550567 A1 PH12020550567 A1 PH 12020550567A1
Authority
PH
Philippines
Prior art keywords
combination
pyridones
ring
drug against
against tuberculosis
Prior art date
Application number
PH12020550567A
Other languages
English (en)
Inventor
Christina Leigh Stallings
Gregory Alexander Harrison
Fredrik Almqvist
Souvik Sarkar
Original Assignee
Quretech Bio Ab
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quretech Bio Ab, Univ Washington filed Critical Quretech Bio Ab
Publication of PH12020550567A1 publication Critical patent/PH12020550567A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PH12020550567A 2017-10-05 2020-05-05 Ring-fused thiazolino 2-pyridones in combination with a drug against tuberculosis PH12020550567A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762568430P 2017-10-05 2017-10-05
US201862716054P 2018-08-08 2018-08-08
PCT/EP2018/077222 WO2019068910A1 (en) 2017-10-05 2018-10-05 THIAZOLINO 2-PYRIDONES WITH A FUSED CYCLE IN COMBINATION WITH A MEDICINE AGAINST TUBERCULOSIS

Publications (1)

Publication Number Publication Date
PH12020550567A1 true PH12020550567A1 (en) 2021-04-26

Family

ID=63840820

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12020550567A PH12020550567A1 (en) 2017-10-05 2020-05-05 Ring-fused thiazolino 2-pyridones in combination with a drug against tuberculosis

Country Status (7)

Country Link
US (1) US11129816B2 (enExample)
EP (1) EP3691619A1 (enExample)
JP (1) JP7233059B2 (enExample)
KR (1) KR20200066315A (enExample)
CN (1) CN111246848A (enExample)
PH (1) PH12020550567A1 (enExample)
WO (1) WO2019068910A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110799513B (zh) * 2017-06-13 2023-04-14 快尔生物技术公司 环稠合噻唑并-2-吡啶酮、其制备方法及其治疗和/或预防涉及革兰氏阳性菌的疾病的应用
AU2019459233B2 (en) * 2019-07-30 2025-04-10 Qurient Co., Ltd. Different forms of 6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy)phenyl)piperidine-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide
WO2021224501A1 (en) 2020-05-08 2021-11-11 Quretech Bio Ab Ring-fused 2-pyridone compounds, methods for preparation thereof and their use in the treatment and/or prevention of a disease involving gram-positive bacteria
CN112921107A (zh) * 2020-12-31 2021-06-08 深圳市慢性病防治中心(深圳市皮肤病防治研究所、深圳市肺部疾病防治研究所) 结核分枝杆菌异质性耐药检测方法、试剂盒及应用
CN113045494B (zh) * 2021-03-29 2022-04-26 四川大学华西医院 吡啶酮衍生物及其在制备预防和/或治疗结核分枝杆菌所引起的结核病的药物中的用途
CN115531388B (zh) * 2022-11-04 2024-03-22 首都医科大学附属北京胸科医院 治疗结核病的药物组合物
CN118593520B (zh) * 2024-05-23 2025-01-24 蚌埠医科大学 化合物k67在制备抗结核药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201502109VA (en) 2010-03-18 2015-05-28 Pasteur Institut Korea Anti-infective compounds
KR20140093610A (ko) 2011-04-21 2014-07-28 재단법인 한국파스퇴르연구소 소염 화합물
EP2997470A4 (en) 2013-05-13 2017-01-18 Telefonaktiebolaget LM Ericsson (publ) Node in a telecommunications network, a virtual network element and methods for retrieving resource identification information
WO2014185853A1 (en) * 2013-05-14 2014-11-20 Quretech Bio Ab Compounds and methods for treatment of chlamydia infections
AU2014295100B2 (en) * 2013-07-26 2019-01-03 Sanofi Antitubercular composition comprising rifampicin, isoniazid, ethambutol and pyrazinamide and its process of preparation.
US20160185774A1 (en) * 2013-08-02 2016-06-30 Institut Pasteur Korea Anti-Infective Compounds
CA2966960C (en) 2014-11-13 2022-09-27 Quretech Bio Ab 2,3-dihydro-thiazolo[3,2-a]pyridin-5-one derivatives, intermediates thereof, and their use as antibacterial agents
CA3019741A1 (en) * 2016-04-08 2017-10-12 Quretech Bio Ab Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis

Also Published As

Publication number Publication date
KR20200066315A (ko) 2020-06-09
EP3691619A1 (en) 2020-08-12
JP7233059B2 (ja) 2023-03-06
CN111246848A (zh) 2020-06-05
RU2020113346A3 (enExample) 2022-04-14
JP2020536085A (ja) 2020-12-10
WO2019068910A1 (en) 2019-04-11
US11129816B2 (en) 2021-09-28
US20200316036A1 (en) 2020-10-08
RU2020113346A (ru) 2021-11-09

Similar Documents

Publication Publication Date Title
PH12020550567A1 (en) Ring-fused thiazolino 2-pyridones in combination with a drug against tuberculosis
USD810782S1 (en) Cellular phone with graphical user interface
WO2016011390A8 (en) Irak4 inhibiting agents
PH12016501813B1 (en) 1,3-benzodioxole derivative
USD813908S1 (en) Cellular phone with graphical user interface
USD813272S1 (en) Cellular phone with graphical user interface
USD827982S1 (en) Pocket for pants' legs
EP3804846A3 (en) Design, synthesis and characterization of metal organic frameworks
WO2019203753A3 (en) The pharmaceutical combination comprising dapoxetine, phosphodiesterase type-5 inhibitor and anti-emetic agent
USD735266S1 (en) Type font
ZA202200511B (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis
AU2015211852A1 (en) Heterocyclic sulfonamide derivative and medicine comprising same
HK1200313A1 (en) Rasagiline citramide
MX2019010950A (es) Composicion de fotosensibilizador que contiene fenalen-1-ona, compuesto de fenalen-1-ona, asi como su uso.
EP3932917A3 (en) Substituted phenyloxazolidinones for antimicrobial therapy
NZ729064A (en) Heterobicyclic compounds and their use for the treatment of tuberculosis
WO2016074641A8 (zh) Nadh或其盐在制备治疗苯丙酮尿症药物或保健品的应用
PH12020550403A1 (en) Nitrogen-containing heteroaryl compound, and pharmaceutical use thereof
NZ730816A (en) Quinoline carboxamides for use in the treatment of multiple myeloma
NZ732704A (en) Quinoline carboxamides for use in the treatment of leukemia
IN2014DN10669A (enExample)
USD811436S1 (en) Cellular phone with graphical user interface
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.
WO2015142865A3 (en) Metakaryocidal treatments
MX2015003329A (es) Formulaciones farmaceuticas de tetrandrina y metodo.